Before starting enrollment
Conditions
Interventions
Evaluation and encouraging in terms of energy-balanced life style and oral administration of pancrelipase (600 mg a day for 24 weeks)
Evaluation and encouraging in terms of energy-balanced life style
Sponsors
Uonuma Institute of Community Medicine, Niigata Medical and Dental Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Ultrasound reveals fatty liver as two or more following criteria are fulfilled. i. Liver/kidney contrast ii. Vascular blurring in the liver iii. Deep-attenuation of echo-beam in the liver 2) Shear wave elastography is 1.41 m/sec or faster. 3) A written informed consent is obtained from a patient him/her self.
Exclusion criteria
Exclusion criteria: 1) HBV positive 2) HCV positive including a SVR12 case 3) Alcohol consumption more than 20g/day 4) An organic diseases of pancreas or a past History of chronic pancreatitis 5) Allergy against porcine proteins 6) Already taking pancrelipase 7) Taking a medication for diabetes mellitus or HbA1c is 8 or higher 8) Serum triglyceride concentration is 1000 mg/dl or higher 9) Other serious conditions judged to be inadequate by a responsible doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ultrasound findings for fatty liver 24 weeks after the enrollment | — |
Secondary
| Measure | Time frame |
|---|---|
| Shear wave velocity of the liver evoked by acoustic radiation force impulse | — |
Countries
Japan
Contacts
Public ContactTakeshi Suda
Uonuma Institute of Community Medicine, Niigata Medical and Dental Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed